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ER attendance, costs were calculated multiplying resource use by corresponding unit 
costs. Regarding hospitalization, length of stay was multiplied by daily cost obtained 
through hospitals accountancy. Both costs were summed and descriptive statistics 
were calculated. Productivity loss cost within ER admission and hospitalization was 
calculated for employed patients using the Human Capital Approach. Results: 238 
patients were enrolled and 105 (44%) were hospitalized. These patients had a median 
length of stay of 5.4 days and were most commonly hospitalized at the Internal 
Medicine department (n= 80; 76%). Nine patients (8.6%) died during hospitalization. 
Hospitalized patients had the following average (range) costs: pre-hospital care and 
transport € 34 (€ 0-€ 92); emergency room € 218 (€ 58-€ 1,348); hospitalization € 2,880 
(€ 140-€ 26,486); productivity loss costs due to ER and hospitalization € 31 (€ 0-€ 1,579). 
Thus, mean total cost per hypoglycemic event leading to hospitalization was € 3,163 
(€ 230-€ 26,818). ConClusions: We conclude that severe hypoglycemia represent a 
substantial cost to Society and to the public hospitals of the National Health System 
in particular for those cases requiring hospitalization.
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objeCtives: Hypoglycemia, which if left untreated, can be severe and result in sei-
zures, unconsciousness, and coma, during which another person’s help is required to 
administer a rescue dose of glucagon. Injectable glucagon kits are difficult to use and 
require training to administer. This study aimed to quantify the economic impact of 
using glucagon kits on resource use and costs, and identify evidentiary gaps requiring 
future research. Methods: A conceptual model was developed illustrating the series 
of events resulting from a SHE: successful administration of glucagon, ambulance 
calls, transport to the ED, inpatient admission, and outpatient follow-up. A literature 
search was conducted to assess service use and costs associated with severe hypo-
glycemia events (SHE). English language articles were reviewed in PubMed, EMBASE 
and Cochrane databases. Results: Resource use associated with SHE, as a function 
of successful administration of glucagon, has not been systematically evaluated in the 
literature. Uncertainty exists for the probability of receiving a glucagon prescription 
for diabetics and successful use of glucagon kits. Furthermore, based on success-
ful administration of glucagon, the probability of ambulance calls, transports to the 
ED, inpatient admissions, and frequency of outpatient follow-up are lacking in the 
literature. ConClusions: Diabetes is a costly condition for payers, and a common 
complication is hypoglycemia. Glucagon kits are effective in stabilizing diabetics’ 
blood glucose levels during SHE; however, oftentimes physicians do not prescribe, 
patients do not fill, or caregivers do not successfully administer glucagon due to 
the complex administration procedures. As less complicated glucagon products are 
developed, their value propositions must be informed by the economic implications 
resulting from the complex administration requirements of current kits. However, the 
current literature does not systematically evaluate these implications. Consequently, 
future research is needed to quantify the impact of non-successful administration of 
glucagon rescue kits, as well as the extent of under-utilization.
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objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter national 
study to describe the patient population of type 2 diabetics with hypoglycemic epi-
sodes that enter the emergency department caused by an anti-hyperglycemic agent 
(AHA). A key secondary objective is to estimate health care resource consumption 
and costs associated with this type of hypoglycemias. Methods: The study was con-
ducted in 7 centers in mainland Portugal for a period of 12 months (Jan2013-Jan2014). 
Patient level data and resource utilization were collected. Average costs were assessed 
by multiplying 2014 unit costs (available from public sources) with all relevant health 
care resource consumption items registered in the emergency room following the 
hypoglycemia events and through hospital accountancy for the hospitalized patients 
(length of stay x daily mean cost of hospitalization). Results: The study enrolled 238 
patients and the calculated proportion of hypoglycemic episodes among all emer-
gency events in the same period was 0.075% (95%CI: 0.067%, 0.083%). In this popula-
tion, 55.0% of the patients were using insulin, 31.5% were treated with a secretagogue, 
6.7% were on a combination of insulin and a secretagogue oral agent and 6.7% were on 
oral non-secretagogue based AHA therapy. Mean patient age was 76 years and 57.6% 
were females. Estimated mean (range) of direct costs assessed in the emergency room 
were: emergency transportation € 33 (€ 0-€ 92), drugs € 4 (€ 0-€ 45), laboratory workup 56€ 
(€ 8-€ 212), other exams € 72 (€ 0-€ 944), physician and nurse time € 30 (€ 4-€ 211) and € 14 
(€ 1-€ 90), respectively. Mean hospitalization cost was € 1,271 (€ 0-€ 26,486). Mean indirect 
cost related with productivity loss within employed patients was € 15 (€ 0-€ 1,579). Total 
cost, including direct and indirect costs, was € 1,493 (€ 34-€ 26,818) per hypoglycemic 
event. Hospitalization was the main cost driver (85% of total costs). ConClusions: 
We conclude that hypoglycemia represent a substantial cost for the Society and in 
particular for the public hospitals of the National Health System.
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passive safety pen device would result in total estimated cost savings of $17,865.40 
annually. ConClusions: The implementation of insulin pen devices in acute care 
results in cost savings, as well as time savings for nurses that may be re-directed to 
increased time at the patient bedside.
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objeCtives: The aim of this study was to assess the epidemiologic and economic 
burden of diabetic retinopathy (DR) in terms of incidence, treatment patterns 
and cost by a population-based study. Methods: Eligible patients were identi-
fied through a data warehouse (DENALI), which matches demographic, clinical 
and economic data of about 9.9 million individuals of Lombardy region. The study 
population consists of all individuals with a diagnosis of diabetes who, during the 
period 1-1-2000 to 31-12-2010 received one of the following health care services: 
hospital admission (HA) for diabetes with ophthalmic manifestations or retinal 
disorders, fluorescein angiography or angioscopy of eye, destruction of chorioretinal 
lesion, repair of retinal tear, injection of vitreous substitute, and repeated oph-
thalmic examinations. The study population was followed for a minimum of 1 to 
a maximum of 10 years. We evaluated demographic characteristics of the study 
population and costs from the National Health Service’s perspective. Results: The 
2000-2010 DR population was estimated to be around 127,000 (52% male). The aver-
age incidence per year and the 2010-prevalence were 6.1 and 24.2 per 100 diabetic 
patients. Median age (min-max) at the index event was 68.6 (0.3-104.4) with 37% 
younger than 65-years. Around 15% of the population had Charlson Comorbidity 
Index> = 1 and the overall mortality was 41.8 deaths/100 patient-years. The 10-year 
mean cost for DR patients were 17,361€ (95%C.I. 12,673-22,050) compared with 4,771€ 
in a control diabetic population without complications. HA costs represented the 
driver of total costs, ranging from 45% (index year) to 36% (last year of follow-up), fol-
lowed by drug (30-34.4%) and outpatient (25-29.7%). During the index year 13% of HA 
and outpatient costs were attributed to eye-specialist departments. Approximately 
1% received intravitreal injections in 2010. ConClusions: This study attempted 
to describe the burden of DR in Italy revealing socio-economic aspects relevant in 
terms of incidence and costs.
PDB114
evaluaTion of The BurDen of illneSS of u.S. meDicare PaTienTS 
DiaGnoSeD wiTh hyPerPoTaSSemia
Xie L.1, Dysinger A.H.1, Kariburyo M.F.1, Du J.1, Baser O.2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research and The University of 
Michigan, Ann Arbor, MI, USA
objeCtives: To evaluate the economic burden and health care utilization of patients 
diagnosed with hyperpotassemia in the U.S. Medicare population. Methods: 
Hyperpotassemia patients (International Classification of Disease 9thRevision 
Clinical Modification ICD-9-CM diagnosis codes 276.7) were identified from the U.S. 
national Medicare claims from 01JAN2009 through 31DEC2011. The first diagnosis 
date was designated as the index date for the hyperpotassemia cohort. Patients 
without a hyperpotassemia diagnosis but of the same age, region, gender, index 
year and matched baseline Charlson Comorbidity Index score were identified for 
the comparison cohort, with a randomly-chosen index date to minimize selec-
tion bias. Patients were required to have continuous medical and pharmacy ben-
efits 1 year before and after the index date. Study outcomes (health care costs and 
utilizations) were compared between the disease and comparator cohorts using 
1: 1 propensity score matching (PSM). Results: A total of 90,528 patients were 
included in the hyperpotassemia and comparison cohorts. After 1: 1 PSM, 28,929 
patients were matched from each cohort, and baseline characteristics were pro-
portionate. Patients diagnosed with hyperpotassemia were more likely to utilize 
health care resources, including Medicare carrier (98.4% vs. 77.8%), Durable Medical 
Equipment (DME; 36.7% vs. 23.6%) and Home Health Agency (HHA; 18.4% vs. 7.3%) 
claims, outpatient visits (75.5% vs. 47.7%), inpatient (37.4% vs. 3.4%), skilled nursing 
facility (SNF, 13.3% vs. 3.4%) and hospice stays (1.1% vs. 0.8%) and prescription drug 
claims (54.1% vs. 50.7%). Patients diagnosed with hyperpotassemia also incurred 
higher Medicare carrier ($3,447 vs. $1,636), DME ($343 vs. $167), HHA ($938 vs. $412), 
outpatient ($11,006 vs. $4,534), inpatient ($7,156 vs. $1,463), SNF ($2,688 vs. $612), 
hospice ($244 vs. $198), pharmacy ($1,104 vs. $812) and total costs ($26,926 vs. $9,834) 
(p< 0.05). ConClusions: The economic burden and health care resource utilization 
were significantly higher for patients diagnosed with hyperpotassemia.
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objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter study aimed 
(a) to describe type 2 diabetes patients treated with an anti-hyperglycemic agent 
(AHA) and admitted to the emergency room (ER) due to a hypoglycemic event and (b) 
to estimate health care resources use and its costs related with the ER hypoglycemic 
episode. In this analysis, costs within hospitalized patients following severe hypo-
glycemia assisted at the ER were specifically calculated. Methods: The study was 
conducted in 7 centers in mainland Portugal for a period of 12 months (Jan 2013 – Jan 
2014). Costs related with these hospitalized patients were calculated considering the 
hospital perspective. Unit costs for 2014 were extracted from official sources and 
reported in euros. Patient level data were used to calculate average costs. Regarding 
